At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 272 enrolled
Drug / intervention
LY2963016 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating LY2963016, Lantus®, and 1 other intervention for Type 1 Diabetes. Completed, enrolled 272 participants across 20 sites.
Detailed Summary
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartMar 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedNov 9, 2017
Enrollment StartMar 23, 2018
Primary CompletionMar 5, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.6 years ago
Interventions
LY2963016drug
Administered SC
Lantus®drug
Administered SC
Insulin Lisprodrug
Administered SC